IL33 and Alzheimer disease: Therefore, we propose that IL‐33 would further enhance type 2 inflammation by activating ILC2 and Th2, leading to a vicious cycle.13, 37 To date, although barrier disruption and overactivation of immunity in AD keratinocytes have been identified individually, our results indicate that the ΔNp63 pathway at least partially integrates these keratinocyte features.